Publicaciones en las que colabora con Luis Jara Palomares (75)

2024

  1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  2. C-reactive Protein and Risk of Right Ventricular Dysfunction and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

    Archivos de Bronconeumologia, Vol. 60, Núm. 6, pp. 344-349

  3. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis

  4. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial

    Chest, Vol. 165, Núm. 3, pp. 673-681

  5. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

  6. Valoración de la disnea persistente y progresión a hipertensión pulmonar tromboembólica crónica tras tromboembolismo pulmonar agudo sintomático. Análisis conjunto del estudio OSIRIS y SYSPPE

    Revista española de patología torácica, Vol. 36, Núm. 1, pp. 47-48

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  3. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study

    Thrombosis Research, Vol. 228, pp. 1-9

  4. The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism

    American Heart Journal, Vol. 257, pp. 62-68

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial

    Thrombosis Journal, Vol. 20, Núm. 1

  3. Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model

    Frontiers in Cardiovascular Medicine, Vol. 9

  4. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

  5. Gravedad de los pacientes ingresados por epoc agudizada en el ensayo clínico SLICE

    Revista española de patología torácica, Vol. 34, Núm. 4, pp. 209-216

  6. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

    Chest, Vol. 161, Núm. 2, pp. 524-534

  7. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 725-734

  8. Major bleeding in patients with pulmonary embolism presenting with syncope

    European journal of clinical investigation, Vol. 52, Núm. 7, pp. e13774

  9. Multidisciplinary Consensus for the Management of Pulmonary Thromboembolism

    Archivos de Bronconeumologia

  10. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9